Malathi DC, Janakiraman K, Thangavelu SVA, Ravichandran D. Enlicitide (Lipfendra): the first oral PCSK9 inhibitor - from macrocyclic peptide innovation to clinical translation. Int J Basic Clin Pharmacol [Internet]. 2026 Aug. 24 [cited 2026 Aug. 25];15(5):1126-34. Available from: https://www.ijbcp.com/index.php/ijbcp/article/view/6446